News | October 31, 2023
Alkem ‘Healthy Lungs' initiative aims to clear the air
The initiative will focus on advocating for cleaner air
The initiative will focus on advocating for cleaner air
The companies plan to start a pivotal Phase 3 trial in the coming months
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
hey were educated about the 7- step hand-washing technique trainings
Subscribe To Our Newsletter & Stay Updated
